European Innovation Council

Established in 2020, the European Innovation Council supports innovative startups and researchers with promising ideas, focusing on early-stage companies with positive environmental, social, or governance impacts. It co-invests alongside private investors.

Nicklas Bergman

Strategic Advisor and IC member

Francoise Birnholz

Affiliate Member

David Malo Jean

Director

Past deals in Europe

VSORA

Venture Round in 2025
VSORA develops digital signal processing IP and chips for 5G networks, featuring a multicore DSP architecture that removes the need for DSP coprocessors and a shared DSP development flow that unites signal processing and software engineers in one environment to speed time-to-market. The company aims to boost DSP computing power while reducing power consumption, improving system performance, and shrinking silicon footprint. Based in France, founded in 2015 by veteran DSP engineers, VSORA serves chipmakers designing next-generation digital communications systems.

AMT Medical

Series B in 2025
AMT Medical B.V., established in 2015 and located in Ede, the Netherlands, specializes in the development of innovative medical devices for heart bypass surgery. The company's flagship product, the AMT Heart Bypass System, utilizes a minimal invasive technique known as the ELANA bypass, which was invented by neurosurgeon Prof. Dr. C.A.F. Tulleken and his research team. This advanced technology aims to enhance traditional heart bypass procedures by making them faster, safer, and less invasive, thereby improving patient outcomes and reducing complications. AMT Medical has completed the full development of its product and the production process, with all pre-clinical trials successfully concluded. The company is also preparing to initiate a clinical multi-center trial to further validate the technology's efficacy.

Sparrow Quantum

Series A in 2025
Sparrow Quantum specializes in developing deterministic single-photon sources for advancing light-matter interfaces in quantum technologies. With a focus on high efficiency, purity, indistinguishability, and outcoupling, the company's technology is based on over two decades of research at the Niels Bohr Institute.

Marvel Fusion

Series B in 2025
Marvel Fusion develops fusion energy technology using a laser-based reactor. Its innovative approach offers clean, safe, and reliable energy solutions, aiming to commercialize baseload fusion electrical power.

Wooptix

Series C in 2025
Founded in Madrid, Spain in 2014, Wooptix develops innovative imaging technologies. The company specializes in creating three-dimensional modulation of images for enhanced volumetric photography and videography, enabling advanced image post-processing.

Stablepharma

Grant in 2025
Founded in 2012, Stablepharma specializes in developing processes for vaccine stabilization. Its flagship product, Stablevax, enables precise dosage pre-loading into syringes at manufacture, eliminating wastage. The company's technology platform converts existing vaccines and diagnostics into thermostable products, addressing global cold chain challenges.

QDI systems

Venture Round in 2025
QDI Systems B.V. is a startup based in Groningen, the Netherlands, focused on developing advanced imaging devices for medical applications using quantum dot technology. The company specializes in creating X-ray sensors that deliver high-contrast and high-resolution imaging, particularly for mammography, while also reducing radiation exposure for patients. QDI Systems aims to provide user-friendly quantum dot materials accompanied by comprehensive instructions for constructing high-performance imaging devices. By leveraging innovative technology, the company enhances the precision of medical imaging, enabling healthcare professionals to obtain critical diagnostic information efficiently and safely.

AlzeCure Pharma

Grant in 2025
AlzeCure Pharma is a Swedish pharmaceutical company dedicated to developing drug therapies targeting diseases affecting the central nervous system. Its primary focus lies in Alzheimer's disease, with five drug candidates at various stages of development.

QDI systems

Grant in 2025
QDI Systems B.V. is a startup based in Groningen, the Netherlands, focused on developing advanced imaging devices for medical applications using quantum dot technology. The company specializes in creating X-ray sensors that deliver high-contrast and high-resolution imaging, particularly for mammography, while also reducing radiation exposure for patients. QDI Systems aims to provide user-friendly quantum dot materials accompanied by comprehensive instructions for constructing high-performance imaging devices. By leveraging innovative technology, the company enhances the precision of medical imaging, enabling healthcare professionals to obtain critical diagnostic information efficiently and safely.

TENSIVE

Series A in 2025
TENSIVE s.r.l. is a biomedical company based in Milan, Italy, founded in 2012. It specializes in the development of innovative prostheses for natural breast reconstruction and augmentation. The company's products utilize biodegradable synthetic biomaterials and feature an internal micro-architecture that mimics blood vessel structures. These vascularized prostheses aim to enhance the quality of life for patients undergoing treatment for breast cancer, offering a solution that reduces the need for recurrent and costly surgical interventions. Through its focus on advanced biomaterials and design, TENSIVE seeks to provide effective and sustainable options for breast reconstruction.

.Lumen

Venture Round in 2025
Dotlumen is a research startup founded in 2020 and based in Cluj, Romania, focused on enhancing the quality of life for visually impaired individuals. The company develops innovative glasses equipped with a sensory and feedback system that aids users in navigating their environments. By leveraging advancements in artificial intelligence, robotics, and neuroscience, Dotlumen aims to empower blind individuals to better understand and interact with the world around them.

Photon IP

Grant in 2025
Photon IP is a Dutch deeptech company based in Eindhoven. It specializes in developing advanced photonics technologies for various applications.

GBM Works

Seed Round in 2024
GBM Works is a Netherlands-based company that develops offshore wind turbine foundation installation technologies. Founded in 2016 and based in The Hague, it focuses on methods for installing foundations with minimal environmental impact, including a silent installation approach designed to reduce noise pollution and disruption to marine life. The company's solutions aim to enable faster deployment of offshore wind projects while supporting sustainability goals in renewable energy.

Onward

Grant in 2024
Onward is a medical technology company focused on developing therapies aimed at enabling functional recovery for individuals with spinal cord injuries. The company is creating an Implantable Neuro-stimulation System (INS) that features real-time motion feedback and utilizes training tools for rehabilitation. Onward has developed two platforms for neurostimulation: ARCIM, an implantable system, and ARCEX, a non-invasive transcutaneous system. To establish its customer base, Onward has targeted the United States and four European markets, namely Germany, France, the United Kingdom, and the Netherlands.

Innoventric

Series B in 2024
Innoventric is an Israeli medical device company specializing in percutaneous solutions for Tricuspid Regurgitation and right heart disease. Founded in 2017, the company's flagship product is the Trillium™ technology, designed to treat Tricuspid Valve Regurgitation through functional valve replacement using Cross-Caval anchoring and a unique multi-valve design.

INBRAIN Neuroelectronics

Series B in 2024
INBRAIN Neuroelectronics is a medical device company based in Barcelona, Spain, founded in 2019. It specializes in developing graphene-based neural interfaces and intelligent neuromodulation systems aimed at treating brain disorders. The company has created the world's first graphene-based brain-computer interface (BCI) therapeutics platform, which integrates precise BCI decoding with micrometric modulation. This innovative technology allows for real-time monitoring and adaptive, personalized treatments for conditions such as Parkinson's disease, epilepsy, and stroke rehabilitation. By utilizing AI-driven solutions, INBRAIN maximizes therapeutic outcomes while minimizing side effects. The company is also expanding its capabilities through strategic partnerships, including collaborations with Merck KGaA and its subsidiary INNERVIA Bioelectronics, to explore applications in peripheral nerve and systemic diseases, advancing the field of neurotechnology and bioelectronics.

National University of Ireland, Maynooth

Grant in 2024
Maynooth University is internationally recognised for quality and value of Their research and scholarship and Their dedication and commitment to teaching and Their students. Part of the NUI and formally established as an autonomous university in 1997, Maynooth University traces its origins to the foundation of the Royal College of St. Patrick in 1795, drawing inspiration from a heritage that includes over 200 years of education and scholarship. The University is a place of lively contrasts. It is a modern institution, dynamic, rapidly-growing, research-led and engaged, yet grounded in historic academic strengths and scholarly traditions.

.Lumen

Venture Round in 2024
Dotlumen is a research startup founded in 2020 and based in Cluj, Romania, focused on enhancing the quality of life for visually impaired individuals. The company develops innovative glasses equipped with a sensory and feedback system that aids users in navigating their environments. By leveraging advancements in artificial intelligence, robotics, and neuroscience, Dotlumen aims to empower blind individuals to better understand and interact with the world around them.

Axelera AI

Series B in 2024
Axelera AI specializes in developing hardware and software platforms designed to accelerate artificial intelligence tasks, particularly for edge computing. Its flagship product, the Metis™ AI Platform, integrates both hardware and software components to deliver high-performance, energy-efficient AI inference solutions. The company is headquartered in Eindhoven with R&D offices in Belgium, Switzerland, and Italy.

Qblox

Series A in 2024
Qblox is a Dutch scaleup specializing in quantum technology, focused on developing patented solutions for the scalable control of quantum computers. The company designs and manufactures modular control hardware that simplifies the experimental setups involving qubits, employing a distributed processor architecture to enhance gate fidelities. By advancing electronics with improved noise and drift performance, Qblox enables scientists to minimize crosstalk and achieve low-latency arbitrary control flows while optimizing measurement efficiency in dynamic readout conditions. The company aims to address the scientific and engineering challenges that must be overcome to transition from prototype quantum computers to powerful, practical quantum processors.

King's College London

Grant in 2024
King's College London is a public research university in London, United Kingdom, and a constituent college of the University of London. Founded in 1829 by King George IV and the Duke of Wellington, it operates from multiple central London campuses and a campus in Denmark Hill, with a strong emphasis on medical and biomedical research and education. The institution supports a large community of students and staff and is known for its extensive graduate and postgraduate programmes. It is a founding member of the King's Health Partners academic health sciences centre and participates in major research and academic networks, including the Russell Group and Universities UK.

Tilkal

Venture Round in 2024
Tilkal develops a software infrastructure that organizes traceability across various supply chain stakeholders. Founded in 2017, the company is headquartered in Paris, France.

Basemark

Series B in 2024
Basemark specializes in developing augmented reality software for enhanced driver awareness and safety. It offers tools to avoid occlusion, prevent motion sickness, and support multiple in-vehicle displays, enabling automotive manufacturers to create practical AR applications.

E-peas

Venture Round in 2024
E-peas SA is a Belgian company established in 2014, specializing in the design and manufacturing of electronic systems that provide energy autonomy for Internet of Things (IoT) applications. The company develops innovative energy harvesting solutions that enable devices to draw energy from various ambient sources, including solar, thermal, vibration, and radiofrequency. E-peas produces energy harvesting power management integrated circuits (PMICs) and microcontrollers that enhance the performance and longevity of IoT devices by either extending battery life or eliminating the need for batteries altogether. Their technology caters to a wide range of sectors, including home automation, healthcare, retail, and agriculture, thereby facilitating the creation of smarter and more energy-efficient connected devices. Headquartered in Mont-Saint-Guibert, Belgium, E-peas aims to transform the landscape of portable energy solutions.

Ability Pharmaceuticals

Venture Round in 2024
Ability Pharmaceuticals is a drug discovery and development company based in Barcelona, Spain. It develops human therapeutics targeting cell membranes to treat cancer and other indications with unmet medical needs. Ability Pharmaceuticals is focused on developing new drugs for the treatment of lung cancer and pancreatic cancer. The company develops Lipid Analogue Therapeutics, a new drug class that modifies the composition of the cell membrane and displays a capacity to influence the local organization of lipid structures in the cell membrane, inducing the formation of non-lamellar phase structures. Its development pipeline includes ABTL0812 product in preclinical development; and ABTL1014, a drug candidate in preclinical characterization.

Multiverse Computing

Series A in 2024
Founded in 2019 with headquarters in San Sebastian, Spain, Multiverse Computing develops quantum computing software tailored to solve complex real-world challenges. Its software leverages probabilistic technology for portfolio optimization, risk analysis, and market simulation, serving clients across industries such as finance, energy, manufacturing, and logistics.

Daze

Series A in 2024
Daze is an engineering startup focused on creating innovative solutions for electric vehicle charging. Its flagship product, DazePlug, is an automatic charging device that utilizes smart charging ecosystems and energy management systems. This technology enables automatic inductive charging, significantly reducing the time required to charge electric vehicles while eliminating the need for manual handling of cables. DazePlug features a retrofit design that is both waterproof and dustproof, ensuring durability and ease of use. By simplifying the charging process, Daze aims to enhance user experience and convenience for electric vehicle owners.

Palobiofarma

Venture Round in 2024
Palobiofarma is a Spanish biotechnology company based in Barcelona’s Science Park, dedicated to discovering and developing innovative drugs that target adenosine receptors. The company aims to be the first European entity to bring an adenosine modulator to market, focusing on the treatment of diseases such as advanced prostate cancer. Through its expertise in medicinal chemistry and in vitro pharmacology, Palobiofarma is committed to advancing the understanding of adenosine's role in disease and enabling healthcare professionals to improve patient outcomes through novel therapeutic options.

Heart Aerospace

Series B in 2024
Heart Aerospace AB, established in 2018 with headquarters in Gothenburg, Sweden, and operations in Palo Alto, California, specializes in developing electric regional airliners certified for passenger flight. The company's mission is to facilitate swift, affordable, and sustainable travel for regional journeys worldwide. Their flagship aircraft, the ES-19, is a nineteen-passenger electric airliner designed with an operating range of 400 km, aiming to reduce fuel and maintenance costs compared to traditional aircraft while emitting zero operational emissions. Heart Aerospace targets commercial operation certification for the ES-19 by 2026.

NETRIS Pharma

Series A in 2023
NETRIS Pharma S.A.S. is a biotechnology company based in Lyon, France, focused on the identification and development of therapeutic molecules aimed at treating various forms of cancer. Established in 2008, the company specializes in targeting dependence receptors, which are trans-membrane proteins that play a crucial role in cellular signaling and tumor control. NETRIS Pharma conducts both in vitro and in vivo research, as well as preclinical practices, to manufacture drugs specifically for the treatment of breast cancer, lung cancer, glioblastoma, and neuroblastoma. Through its innovative approach, the company aims to advance cancer therapies and contribute to improved patient outcomes in the pharmaceutical industry.

Antabio

Series B in 2023
Antabio is a private biopharmaceutical company based in Labege, France, focused on developing innovative treatments for drug-resistant infections, particularly targeting critical priority pathogens. Founded in 2009, the company specializes in creating novel antibacterial resistance-breakers, including stand-alone inhibitors of bacterial metalloenzymes. These inhibitors are designed to be combined with existing antibiotics, such as carbapenems, to restore their efficacy against the most challenging pathogens responsible for life-threatening infections, including carbapenem-resistant nosocomial pneumonia. Antabio aims to address significant unmet medical needs in the treatment of drug-resistant infections, ultimately providing healthcare professionals with effective medicinal products to combat these critical health challenges. The company has been recognized for its work, receiving a Wellcome Trust Seeding Drug Discovery Award.

Ignion

Venture Round in 2023
Founded in 2015, Ignion specializes in designing and manufacturing antennas tailored for mobile and wireless connectivity. Their off-the-shelf antennas cater to Internet of Things devices, mobile connectivity, and short-range wireless systems, facilitating seamless integration within industrial designs.

ResoTher Pharma

Grant in 2023
ResoTher Pharma is a privately held biotechnology company based in Copenhagen, Denmark. The company specializes in developing peptide-based drugs derived from Annexin A1, an endogenous immunomodulator. These drugs are designed as resolution therapies for diseases where neutrophil-driven inflammation is a key pathological factor. ResoTher Pharma's primary focus is on addressing cardiovascular and inflammatory disorders that have significant unmet medical needs. Their patented peptide drugs target a G-protein coupled receptor expressed on leukocytes, aiming to mimic the body's natural response to resolving inflammation and promoting tissue repair.

SolasCure

Grant in 2023
Founded in 2017, SolasCure is a biotechnology company based in Wales, UK. It specializes in developing innovative hydrogel treatments for patients with chronic wounds. Its flagship product, Aurase, facilitates wound debridement, removing dead or infected tissue to enhance healing.

VSORA

Grant in 2023
VSORA develops digital signal processing IP and chips for 5G networks, featuring a multicore DSP architecture that removes the need for DSP coprocessors and a shared DSP development flow that unites signal processing and software engineers in one environment to speed time-to-market. The company aims to boost DSP computing power while reducing power consumption, improving system performance, and shrinking silicon footprint. Based in France, founded in 2015 by veteran DSP engineers, VSORA serves chipmakers designing next-generation digital communications systems.

FarmInsect

Series A in 2023
FarmInsect GmbH, established in 2019 and headquartered in Bergkirchen, Germany, specializes in automated insect breeding systems. The company develops machines and IoT solutions that enable regional farmers to rear insects on-site for use as animal feed, primarily for chickens, pigs, and fish. This sustainable approach aims to replace imported soy or fishmeal with locally produced protein feed, thereby enhancing the efficiency of animal husbandry while reducing environmental impact.

Nanogence

Venture Round in 2023
Founded in 2017, Nanogence specializes in developing novel material solutions for the construction sector. It focuses on creating synthetic, tailor-made materials that enhance performance and reduce carbon emissions in applications such as construction, pharmaceuticals, and mobility.

Epigene Labs

Convertible Note in 2023
Epigene Labs SAS is a biotechnology firm focused on enhancing precision oncology through its advanced technology platform that utilizes artificial intelligence. Founded in 2019 and headquartered in Paris, France, with an additional office in Boston, Massachusetts, the company addresses the significant challenges of aggregating, analyzing, and visualizing extensive genomic data in cancer research. By integrating proprietary data from partners with publicly available datasets, Epigene Labs provides medical researchers with actionable insights and user-friendly analytics. The company collaborates with leading cancer centers and prominent biotech firms to develop intelligence-augmenting services that support drug discovery and research in precision oncology. Its innovative approach aims to transform genomic data into effective strategies for targeted cancer therapies.

Swisspod Technologies

Grant in 2023
Founded in 2019, Swisspod Technologies specializes in designing and developing Hyperloop vessels for tube-based transportation systems. The company aims to create energy-efficient, fully-electric pods, harnessing high-quality Swiss engineering to facilitate sustainable and efficient high-speed travel between cities.

Microsure

Series B in 2023
Founded in 2014, Microsure specializes in enhancing microsurgical procedures. Its flagship product is a motion stabilizer system designed by and for microsurgeons to overcome physical limitations and improve surgical precision. This technology has successfully been used in clinical trials, with the aim of increasing treatment options for patients.

Xeltis

Series D in 2023
Xeltis is a clinical-stage medical device company developing bio-absorbable heart valves and blood vessels. Its RestoreX technology enables the body's natural healing system to create functional tissue within its devices, forming new valves or vessels over time. Headquartered in Zurich, Switzerland, with R&D and manufacturing facilities in Eindhoven, Netherlands, Xeltis aims to transform cardiovascular care.

INBRAIN Neuroelectronics

Grant in 2023
INBRAIN Neuroelectronics is a medical device company based in Barcelona, Spain, founded in 2019. It specializes in developing graphene-based neural interfaces and intelligent neuromodulation systems aimed at treating brain disorders. The company has created the world's first graphene-based brain-computer interface (BCI) therapeutics platform, which integrates precise BCI decoding with micrometric modulation. This innovative technology allows for real-time monitoring and adaptive, personalized treatments for conditions such as Parkinson's disease, epilepsy, and stroke rehabilitation. By utilizing AI-driven solutions, INBRAIN maximizes therapeutic outcomes while minimizing side effects. The company is also expanding its capabilities through strategic partnerships, including collaborations with Merck KGaA and its subsidiary INNERVIA Bioelectronics, to explore applications in peripheral nerve and systemic diseases, advancing the field of neurotechnology and bioelectronics.

ONO

Convertible Note in 2023
Creating transformative change in urban mobility, making our cities cleaner and more enjoyable. We first focus on urban logistics, moving goods around the city in ways that are sustainable, efficient and cost-effective. Our vehicle and its modular platform system, with easily swappable modular units, meets the needs of city logistics. From moving food to flowers to furniture, the possibilities are endless. ONO’s founders, pioneer in e-mobility solutions, Beres Seelbach, former head of design at Mercedes and Volkswagen, Murat Günak, and light electric vehicle expert and engineer, Philipp Kahle, sought to rethink and reshape modern urban transportation. They put together a forward-thinking group of designers, engineers and creative thinkers who shared their vision of transforming urban mobility. ONO is a Berlin-based e-mobility company introducing a whole new category of emissions-free vehicle: the Pedal Assisted Transporter (PAT), combining the flexibility of a bicycle with the capacity and durability of a van. We offer environmentally friendly urban logistics solutions designed and optimised for cities of today.

Scipio Bioscience

Convertible Note in 2023
Scipio Bioscience SAS is a biotechnology company based in Paris, France, founded in 2017. It specializes in manufacturing benchtop kits that provide innovative sample preparation solutions for single-cell studies. These kits are designed for use in sequencing applications across both clinical and basic research, with a particular focus on transcriptomics. Scipio Bioscience's products enable research laboratories to perform single-cell barcoding in a test tube format, facilitating more precise and efficient analysis in various scientific investigations.

Handiscover

Seed Round in 2023
Handiscover Sweden AB is an online booking platform specializing in accommodations for individuals with physical disabilities. Founded in 2014 by Sebastien Archambeaud in response to personal experiences as a parent of a child with a muscle disease, the company is headquartered in Malmö, Sweden. Handiscover features a distinctive classification system that allows users to select accommodations based on varying levels of mobility and physical needs. This community-based platform not only enables individuals with disabilities to find suitable vacation rentals but also assists companies and municipalities in gathering and presenting essential accessibility data. By focusing on the unique requirements of its users, Handiscover aims to enhance the travel experience for people with disabilities, making it easier for them to discover and book accessible holiday accommodations.

Wooptix

Grant in 2023
Founded in Madrid, Spain in 2014, Wooptix develops innovative imaging technologies. The company specializes in creating three-dimensional modulation of images for enhanced volumetric photography and videography, enabling advanced image post-processing.

Wooptix

Series B in 2023
Founded in Madrid, Spain in 2014, Wooptix develops innovative imaging technologies. The company specializes in creating three-dimensional modulation of images for enhanced volumetric photography and videography, enabling advanced image post-processing.

Energy Dome

Series B in 2023
Energy Dome develops a low-cost, efficient system for long-duration electricity storage using liquid CO2. Its focus is on enabling dispatchable renewable energy production to facilitate the decarbonization of the energy industry and promote sustainability.

ADmit Therapeutics

Venture Round in 2023
ADmit Therapeutics is a biotechnology company that develops diagnostic tests for early detection of Alzheimer’s disease. Its blood-based assay uses epigenetic analysis to assess mitochondrial DNA methylation, including methylcytosines, through next-generation sequencing, and does not rely on beta-amyloid or tau markers. The test is intended to aid pharmaceutical research by enabling early diagnosis and streamlined drug development. The company was founded in 2017 and is based in Begues, Spain.

Neuro Event Labs

Convertible Note in 2023
Neuro Event Labs Oy, established in 2015 and headquartered in Tampere, Finland, specializes in developing artificial intelligence-based software for epilepsy patient monitoring. Their primary product collects accurate seizure data from patients at home and in hospitals, which is then analyzed and relayed to physicians for informed treatment decisions. This solution was developed in close collaboration with leading Finnish hospitals.

Plasmacure

Convertible Note in 2023
Plasmacure, headquartered in Eindhoven, Netherlands, is a medical technology company focused on developing innovative solutions for chronic wound healing, with a particular emphasis on diabetic foot wounds. The company's core product is a patented cold plasma solution designed to kill bacteria, stimulate cell proliferation, and improve microcirculation, thereby reducing the risk of amputation and enhancing patients' quality of life.

EBAMed

Series A in 2023
EBAMed develops a non-invasive ultrasound-based device to monitor and treat heart motion using proton beams. Founded in 2018, the company is based in Geneva, Switzerland.

TreaTech

Series A in 2023
TreaTech is a Swiss cleantech company established in 2015 by engineers from the École Polytechnique Fédérale de Lausanne (EPFL). The company specializes in developing catalytic hydrothermal gasification (cHTG) technology that offers an innovative approach to wastewater treatment. This thermochemical process effectively transforms various types of liquid waste, including sewage sludge, into valuable by-products such as renewable gas, clean water, and mineral salts. TreaTech's solutions focus on eco-friendly waste disposal, aligning with sustainable development and circular economy principles. By recycling wastewater and its by-products, TreaTech enables clients to manage waste more sustainably while generating resources like fertilizers and biogas.

Sparrow Quantum

Seed Round in 2023
Sparrow Quantum specializes in developing deterministic single-photon sources for advancing light-matter interfaces in quantum technologies. With a focus on high efficiency, purity, indistinguishability, and outcoupling, the company's technology is based on over two decades of research at the Niels Bohr Institute.

VCG.AI

Grant in 2023
VCG.AI develops AI-powered software to accelerate the circular economy by turning industrial by-products and waste into valuable resources. Its platform, including the Value Chain Generator, analyzes thousands of data points to identify, evaluate, and implement circular business models and resource reuse strategies. It integrates real-time data analytics, technology readiness assessments, patent landscape analysis, supplier mapping, and value-chain tracking to shorten development cycles and improve resource efficiency. The solution supports organizations, cities, and regions in valorising by-products, sourcing circular materials, and enhancing circularity across supply chains. VCG.AI maintains a library of validated circular solutions and technologies and operates across Europe, helping customers accelerate market entry and create more sustainable, resilient operations.

Naco

Grant in 2023
Naco Technologies Ltd is a manufacturer and supplier of advanced nano-coating technologies, specializing in high-performance coatings for various industries including tooling, automotive, aerospace, and microchip production. Founded in 2009 and headquartered in Riga, Latvia, Naco develops multilayer and multicomponent coatings that enhance equipment performance by providing oil-enhanced, wear-protective, thermal barrier, and liquid-repellent properties. The company plays a significant role in the hydrogen sector by creating specialized coatings for Green Hydrogen systems, such as electrolyzers and fuel cells, which improve the reliability of these systems while minimizing the use of costly and scarce materials. In 2015, Naco Technologies was acquired by the Schaeffler Group, a Germany-based company, further strengthening its capabilities and market reach.

Bluedrop Medical

Venture Round in 2023
Founded in 2014, Bluedrop Medical develops an IoT-enabled device for early detection of diabetic foot ulcers. Its home-based system scans patients' feet daily, sends data to the cloud for analysis, and alerts healthcare providers to potential abnormalities, reducing amputation risks.

nyris

Venture Round in 2023
nyris is a visual search platform provider that enables users to find products and objects in images and videos using AI and neural networks. The platform serves multiple industries, including retail and e-commerce, industrial and manufacturing, media and entertainment, and financial services, by delivering fast, unified search results and improved discovery. Founded in 2015 and headquartered in Berlin with a second location in Düsseldorf, nyris serves customers across more than 50 countries.

Nemysis

Grant in 2023
Nemysis Limited is a specialty pharmaceutical company based in Dublin, Ireland, founded in 2005. The company focuses on addressing unmet needs in nutritional disorders and deficiencies through a staged approach to product development. Nemysis manufactures food supplements, medical matrix products, and prescription items, targeting the same conditions across different market segments. Among its innovative offerings are a gastric and trypsin-resistant glutenous product for oral enzymatic therapy aimed at celiac disease patients, as well as an iron supplement designed to minimize gastrointestinal side effects associated with iron supplementation. Additionally, the company is developing a glutenous medical device that effectively destroys gluten, helping to prevent symptoms in individuals with celiac disease and non-celiac gluten sensitivity.

Samplix

Grant in 2023
Samplix is a biotechnology company based in Herlev, Denmark, that specializes in advanced sample preparation for single DNA and RNA molecules. The company has developed the proprietary Xdrop™ technology, which utilizes a unique "water-oil-water" droplet formation to create millions of reaction chambers for handling individual DNA molecules. This innovative technology allows for targeted enrichment of large DNA fragments, addressing the limitations of existing multi-molecule preparation methods. By enabling precise and sensitive sample preparation, Samplix empowers researchers to conduct more informed studies, facilitating the sequencing of genetic regions critical for understanding virus integration and minimizing unintended CRISPR edits. The Xdrop™ system includes both the instrumentation and consumables needed for effective single-molecule analysis, thereby enhancing the ease of use and efficiency in molecular research.

Samplix

Venture Round in 2023
Samplix is a biotechnology company based in Herlev, Denmark, that specializes in advanced sample preparation for single DNA and RNA molecules. The company has developed the proprietary Xdrop™ technology, which utilizes a unique "water-oil-water" droplet formation to create millions of reaction chambers for handling individual DNA molecules. This innovative technology allows for targeted enrichment of large DNA fragments, addressing the limitations of existing multi-molecule preparation methods. By enabling precise and sensitive sample preparation, Samplix empowers researchers to conduct more informed studies, facilitating the sequencing of genetic regions critical for understanding virus integration and minimizing unintended CRISPR edits. The Xdrop™ system includes both the instrumentation and consumables needed for effective single-molecule analysis, thereby enhancing the ease of use and efficiency in molecular research.

Wingtra

Series B in 2023
Wingtra is a Swiss drone manufacturer that designs the WingtraOne, a vertical take-off and landing VTOL fixed-wing drone that combines plane-like efficiency with VTOL versatility to deliver high-precision aerial data for surveying, mapping, and infrastructure projects. The platform supports sectors including construction, mining, agriculture, forestry, environmental monitoring, urban planning, and land management by capturing detailed data over large areas. Founded in 2014 and launching its market-ready product in 2017, Wingtra serves a global customer base through a network of surveying equipment dealers, enabling professionals to digitize and monitor surroundings with reliable flight performance.

Sensius

Convertible Note in 2023
Sensius is a medical device company based in Rotterdam, Netherlands, founded in 2015. It develops a thermotherapy (hyperthermia) system for head and neck cancer that combines proprietary thermal technology with interactive software and integrated microwave sources. The device is designed by clinicians to tailor treatments, using consumable collars to target the head and neck region. The technology aims to augment standard cancer therapies such as radiotherapy and chemotherapy by improving treatment outcomes and quality of life while reducing associated side effects. Sensius markets its system to oncology clinics and is pursuing CE and FDA clearance, with early interest from potential purchasers as regulatory milestones are approached.

Sensius

Venture Round in 2023
Sensius is a medical device company based in Rotterdam, Netherlands, founded in 2015. It develops a thermotherapy (hyperthermia) system for head and neck cancer that combines proprietary thermal technology with interactive software and integrated microwave sources. The device is designed by clinicians to tailor treatments, using consumable collars to target the head and neck region. The technology aims to augment standard cancer therapies such as radiotherapy and chemotherapy by improving treatment outcomes and quality of life while reducing associated side effects. Sensius markets its system to oncology clinics and is pursuing CE and FDA clearance, with early interest from potential purchasers as regulatory milestones are approached.

Valo Therapeutics

Grant in 2023
Valo Therapeutics is an immunotherapy company focused on developing antigen-coated oncolytic viruses as therapeutic vaccines for cancer treatment. Founded in 2016 and based in Oxford, United Kingdom, with an additional office in Helsinki, Finland, the company utilizes its innovative Valo Tx platform, which includes PeptiCRAd, an engineered human oncolytic adenovirus. This platform is designed to induce systemic anti-tumor T cell responses by transforming oncolytic adenoviruses into targeted, tissue-specific cancer vaccines without requiring the production of multiple genetically modified viruses. Valo Therapeutics is also advancing other neoantigen strategies, including PeptiENV, in collaboration with Professor Vincenzo Cerullo from the University of Helsinki, to enhance therapeutic responses against various cancer types.

Voiseed

Venture Round in 2023
Voiseed is an Italian startup focused on artificial intelligence in synthetic speech technology. The company has developed a fast and scalable AI Dubbing Platform specifically for the video game industry, enabling the creation of virtual human voices that mimic human emotions and prosody. This cloud-based software leverages advanced generative AI technologies to produce highly expressive virtual voices, allowing creators to customize vocal expressions and achieve multilingual voice conversion for various projects. By streamlining the dubbing process, Voiseed aims to reduce costs, time, and complexity, while continuously expanding its features to cater to additional sectors beyond gaming.

TILT Biotherapeutics

Venture Round in 2023
TILT Biotherapeutics Ltd is a preclinical stage biotechnology company based in Helsinki, Finland, specializing in the development of genetically modified oncolytic viruses to enhance T-cell therapies for cancer treatment. Established in 2013, the company focuses on utilizing its patented technology to improve tumor-infiltrating lymphocyte (TIL) and chimeric antigen receptor (CAR-T) therapies, as well as checkpoint inhibiting antibody treatments. TILT Biotherapeutics is advancing products such as TILT-123, TILT-234, and TILT-321, which aim to modify the tumor microenvironment and boost immune responses against cancer. The company's innovative approach holds promise for achieving effective results in treating solid tumors, paralleling the successes seen in hematological tumors.

TILT Biotherapeutics

Grant in 2023
TILT Biotherapeutics Ltd is a preclinical stage biotechnology company based in Helsinki, Finland, specializing in the development of genetically modified oncolytic viruses to enhance T-cell therapies for cancer treatment. Established in 2013, the company focuses on utilizing its patented technology to improve tumor-infiltrating lymphocyte (TIL) and chimeric antigen receptor (CAR-T) therapies, as well as checkpoint inhibiting antibody treatments. TILT Biotherapeutics is advancing products such as TILT-123, TILT-234, and TILT-321, which aim to modify the tumor microenvironment and boost immune responses against cancer. The company's innovative approach holds promise for achieving effective results in treating solid tumors, paralleling the successes seen in hematological tumors.

Modvion

Convertible Note in 2023
Modvion AB is a Swedish company founded in 2015 and based in Gothenburg, specializing in the design and development of modular wind power towers constructed from renewable composite materials. The company focuses on simplifying construction logistics and improving cost efficiency in the wind energy sector through its patented modular technology. This innovative approach enables the production of wind towers exceeding 120 meters in height while significantly reducing transportation costs, installation complexity, and the reliance on traditional steel structures. By leveraging engineered wood products, Modvion aims to enhance the economic viability of wind power projects, ultimately contributing to increased electricity production and more sustainable energy solutions.

Kvantify

Grant in 2023
Founded in 2022, Kvantify is headquartered in Copenhagen, Denmark. It specializes in quantum computing management software, offering solutions to address computational challenges across various industries such as life sciences, financial services, and logistics.

N2 Applied

Private Equity Round in 2023
N2 Applied is a Norwegian technology company focused on enabling farmers to produce their own sustainable fertilizer through an innovative process that utilizes slurry, air, and electricity. The company is in the pre-commercial phase and has developed a technology that allows for the local production of nitrogen-rich fertilizer from liquid organic substrates, such as livestock manure. By integrating nitrogen from the atmosphere into these substrates, N2 Applied's solution not only enhances the nitrogen content but also mitigates ammonia loss and reduces greenhouse gas emissions. The company operates its head office in Oslo/Asker and maintains a test center in Svene, with additional branches in Wageningen and York. N2 Applied's scalable process aims to eliminate the lengthy and costly supply chains associated with traditional fertilizer production, facilitating a more circular farming system. This approach not only provides farmers with cost-effective and environmentally friendly fertilizer but also contributes to on-farm reductions in methane and ammonia emissions.

Ganymed Robotics

Series B in 2023
Ganymed Robotics is a medical device company that develops robotics technologies for orthopedic surgeons, including a therapeutic device designed to improve precision in knee replacement procedures. Founded in 2018 and based in Paris, the company aims to enhance surgical accuracy, reduce operating times, and improve patient outcomes by integrating robotics into the orthopedic workflow.

Daze

Convertible Note in 2022
Daze is an engineering startup focused on creating innovative solutions for electric vehicle charging. Its flagship product, DazePlug, is an automatic charging device that utilizes smart charging ecosystems and energy management systems. This technology enables automatic inductive charging, significantly reducing the time required to charge electric vehicles while eliminating the need for manual handling of cables. DazePlug features a retrofit design that is both waterproof and dustproof, ensuring durability and ease of use. By simplifying the charging process, Daze aims to enhance user experience and convenience for electric vehicle owners.

Energy Dome

Grant in 2022
Energy Dome develops a low-cost, efficient system for long-duration electricity storage using liquid CO2. Its focus is on enabling dispatchable renewable energy production to facilitate the decarbonization of the energy industry and promote sustainability.

iThera Medical

Venture Round in 2022
iThera Medical develops biomedical imaging technology based on photonic molecular imaging and multispectral optoacoustic tomography (MSOT) for preclinical and clinical applications. The company leverages the photoacoustic effect to visualize and quantify anatomical, functional, and molecular information in vivo, including deep tissue visualization and real-time imaging, enabling non-invasive assessment of tumors and inflammatory diseases. Founded in 2010 as a spin-off from Helmholtz Zentrum München, iThera Medical focuses on advancing MSOT technology for use in preclinical research and clinical trials, supporting researchers and clinicians in obtaining deeper insights into biological processes without invasive procedures.

Resistell

Series B in 2022
Founded in 2018, Resistell develops and markets a diagnostic device for phenotypic antibiotic susceptibility testing. Its unique method detects movement caused by living bacterial cells to determine bacterial resistance to antibiotics.

ABCDx

Venture Round in 2022
ABCDx is a Geneva-based company that develops and validates biomarker panels and related diagnostics for brain injury care. It aims to identify patients at risk of severe long-term complications after traumatic brain injury or stroke and to educate clinicians on using these tests. The company is building a platform that analyzes brain biomarkers from a finger-prick blood sample to enable rapid, point-of-care diagnosis of brain injuries, supporting timely treatment decisions. Founded in 2014 by researchers from the University of Geneva and related institutes, ABCDx translates biomarker discovery and clinical validation into practical tools for stroke and brain injury management.

Dimenco

Venture Round in 2022
Dimenco develops and markets autostereoscopic 3D technology solutions. Founded in 2010, the company offers displays, components, software, content conversion services, and consultancy for professional and consumer applications.

Deep Render

Grant in 2022
Deep Render is a London-based AI startup spun out from Imperial College London's Department of Computing. It develops AI-powered video and image compression technology that leverages deep learning, density estimation, unsupervised learning, and quantum techniques to improve compression efficiency. The company has proprietary, patented technology in media and biological image compression, with state-of-the-art results delivering at least a 50% efficiency gain over previous standards.

Precisis

Grant in 2022
Precisis is a medical device company founded in 2004 and headquartered in Heidelberg, Baden-Württemberg, Germany. The company focuses on developing innovative products aimed at treating epilepsy and enhancing patients' quality of life. Its flagship device provides individualized brain stimulation through a surgical procedure that places the device beneath the scalp, precisely targeting the origin of epileptic activity in the brain. This technology allows for the delivery of therapeutic currents to specific areas, enabling effective treatment without direct contact with brain tissue.

Carmat

Grant in 2022
Carmat is a French medtech company that specializes in the development and manufacturing of bioprosthetic artificial hearts. Founded in 2008 and headquartered in Vélizy-Villacoublay, the company creates biocompatible, auto-regulated total artificial hearts designed to closely mimic the human heart's structure, including both right and left ventricles. These devices are intended for patients suffering from chronic terminal heart failure classified as class IV by the New York Heart Association, as well as those experiencing acute terminal heart failure due to massive myocardial infarction. Carmat aims to provide a reliable and innovative therapeutic solution for heart failure patients who are ineligible for transplants and have exhausted other treatment options. In addition to the artificial hearts, the company develops the necessary power supply systems and remote diagnostic systems for these devices.

INBRAIN Neuroelectronics

Grant in 2022
INBRAIN Neuroelectronics is a medical device company based in Barcelona, Spain, founded in 2019. It specializes in developing graphene-based neural interfaces and intelligent neuromodulation systems aimed at treating brain disorders. The company has created the world's first graphene-based brain-computer interface (BCI) therapeutics platform, which integrates precise BCI decoding with micrometric modulation. This innovative technology allows for real-time monitoring and adaptive, personalized treatments for conditions such as Parkinson's disease, epilepsy, and stroke rehabilitation. By utilizing AI-driven solutions, INBRAIN maximizes therapeutic outcomes while minimizing side effects. The company is also expanding its capabilities through strategic partnerships, including collaborations with Merck KGaA and its subsidiary INNERVIA Bioelectronics, to explore applications in peripheral nerve and systemic diseases, advancing the field of neurotechnology and bioelectronics.

INBRAIN Neuroelectronics

Venture Round in 2022
INBRAIN Neuroelectronics is a medical device company based in Barcelona, Spain, founded in 2019. It specializes in developing graphene-based neural interfaces and intelligent neuromodulation systems aimed at treating brain disorders. The company has created the world's first graphene-based brain-computer interface (BCI) therapeutics platform, which integrates precise BCI decoding with micrometric modulation. This innovative technology allows for real-time monitoring and adaptive, personalized treatments for conditions such as Parkinson's disease, epilepsy, and stroke rehabilitation. By utilizing AI-driven solutions, INBRAIN maximizes therapeutic outcomes while minimizing side effects. The company is also expanding its capabilities through strategic partnerships, including collaborations with Merck KGaA and its subsidiary INNERVIA Bioelectronics, to explore applications in peripheral nerve and systemic diseases, advancing the field of neurotechnology and bioelectronics.

FOx Biosystems

Grant in 2022
FOx Biosystems is a biotechnology company focused on enhancing biomolecular interaction analysis for life science research and industry. Founded in 2017 by Filip Delport and Jeroen Lammertyn, and based in Temse, Oost-Vlaanderen, Belgium, the company specializes in developing custom applications, including probes and devices, to support various research needs. FOx Biosystems employs real-time, label-free analysis technology that offers significant advantages over traditional biomolecular analysis tools, such as ease of use, speed, and cost-effectiveness. This technology enables healthcare companies and researchers to obtain high-quality biomolecular data, including concentration measurements, affinity data, and kinetic data, ultimately aiming to transform the life sciences sector.

Ekkono Solutions AB

Venture Round in 2022
Ekkono Solutions AB develops machine learning for the Internet of Things. It provides an embedded analytics engine that runs on connected devices, handling the full workflow from data input and model training to model deployment, retraining and data output. The company serves IoT applications across industries such as energy, telecom, automotive, agriculture, healthcare and housing automation, as well as consumer IoT products including home security gateways, e-bikes and lawnmower robots. Based in Tvååker, Sweden, Ekkono emphasizes edge processing to learn the normal state of each device, enabling anomaly detection, impact analysis, and proactive planning. By processing data locally, it reduces network load and sends only relevant information to the cloud for further analysis, supporting real-time decisions and end-to-end data management.

TENSIVE

Venture Round in 2022
TENSIVE s.r.l. is a biomedical company based in Milan, Italy, founded in 2012. It specializes in the development of innovative prostheses for natural breast reconstruction and augmentation. The company's products utilize biodegradable synthetic biomaterials and feature an internal micro-architecture that mimics blood vessel structures. These vascularized prostheses aim to enhance the quality of life for patients undergoing treatment for breast cancer, offering a solution that reduces the need for recurrent and costly surgical interventions. Through its focus on advanced biomaterials and design, TENSIVE seeks to provide effective and sustainable options for breast reconstruction.

Reblade

Grant in 2022
Reblade specializes in drone-based and AI-assisted repair of wind turbine blades using patented technology. This climate-focused company aims to reduce CO2 emissions by enhancing the efficiency of wind energy production. They seek strategic partnerships and impact investors across Europe, India, and the US.

Nano4Imaging

Grant in 2022
Nano4Imaging GmbH, established in 2011 and located in Aachen, Germany, specializes in the development and production of contrast agents and devices designed for in-vivo imaging of medical implants and minimally invasive devices. The company offers a range of products, including MRWire EmeryGlide, a magnetic resonance imaging (MRI) conditional guidewire, and various coatings under the MagnaFy brand that enhance the visibility of devices in different imaging modalities, such as MRI, computed tomography (CT), and X-ray. These innovations facilitate navigation and monitoring during medical interventions, particularly in the treatment of cardiovascular diseases and in radiotherapy. By leveraging advanced nanotechnology, Nano4Imaging aims to improve the accuracy of patient monitoring and intervention outcomes.

Newronika

Grant in 2022
Newronika is a company dedicated to restoring brain and body functions through innovative neuro-modulation technologies. It translates extensive expertise in biosignal decoding into clinical applications aimed at enhancing treatments, health, and overall wellness. By utilizing a therapeutic device that employs a retro-activity system, Newronika records brain activity and modulates neuro-stimulation to analyze and interpret bio-signals. This technology ensures that patients receive the appropriate stimulation at critical moments, enabling them to engage in normal daily activities and improve their quality of life. Founded as a spin-off from two prominent Italian research institutions, the Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico Hospital and the University of Milan, Newronika prides itself on a multidisciplinary team of scientists specializing in various fields, including neurophysiology, neurology, biomedical engineering, neuropsychology, bioinformatics, and biotechnologies.

Scantrust

Grant in 2022
ScanTrust SA is a company specializing in a cloud-based IoT platform that enhances supply chain visibility and product authentication. Founded in 2014 and headquartered in Lausanne, Switzerland, with operations in Shanghai, Singapore, and Bangkok, ScanTrust employs secure unique identifiers to connect products and packaging to the Internet. Its offerings include a printer portal for packaging and label partners to integrate secure codes into existing processes, an online portal for real-time business intelligence and supply chain insights, and secure QR codes that can be verified by smartphones. This technology enables brand owners to protect their products from counterfeiting while providing detailed supply chain control and opportunities for consumer engagement.

IonKraft

Grant in 2022
IonKraft, a German technology company, specializes in plasma coating for multi-material plastic containers. Their innovative plasma-enhanced chemical vapor deposition process enables recyclability of complex packaging, serving industries such as food, pharmaceuticals, cosmetics, and chemicals. By promoting material reduction and reuse, IonKraft aims to enhance performance while lowering costs, with support from the German Federal Ministry for Economic Affairs and Energy.

ELEM Biotech

Pre Seed Round in 2022
ELEM Biotech SL is a biomedical software company based in Barcelona, Spain, that specializes in creating virtual human models through advanced mathematical modeling and cloud computing. Founded in 2018 by researchers from the Barcelona Supercomputing Center, ELEM has developed a suite of simulation tools known as Alya Red. This platform operates on a Software-as-a-Service model and is designed for the medical device and pharmaceutical industries. Alya Red allows for the simulation of cardiovascular and respiratory systems on virtual patients, utilizing high-performance computing, computational biomechanics, and data analysis. These virtual avatars enable biomedical companies and healthcare professionals to enhance diagnostics, plan treatments, optimize drug delivery, and improve medical devices.

Nexdot

Pre Seed Round in 2022
Nexdot is a company specializing in the development and production of semiconductor nanocrystals known as Quantum Dots, with a particular focus on nanoplatelets—two-dimensional nanosheet Quantum Dots that exhibit enhanced properties. Originating as a spin-off from a renowned academic laboratory in Paris, Nexdot leverages over a decade of expertise in nanomaterial research. The company has invested four years in intensive research and development to establish unique capabilities in the synthesis of colloidal Quantum Dots and Nanoplatelets. Their proprietary materials, characterized by controlled shape and composition, are designed for a variety of applications, including displays, lighting, energy storage, detectors, and bio-imaging. Nexdot combines a team of highly skilled, passionate scientists with seasoned executives who possess a strong background in management and innovation leadership, positioning the company as a leader in the field.

Alesi Surgical

Grant in 2022
Alesi Surgical Ltd. is a company based in Cardiff, United Kingdom, specializing in the development and commercialization of laparoscopic surgical smoke handling systems. Founded in 2009 as a spin-out from the Welsh Institute for Minimal Access Therapy, Alesi Surgical focuses on creating products that enhance the safety, efficiency, and outcomes of surgical procedures. Its innovative tools are portable and suitable for both laparoscopic and robot-assisted surgeries, utilizing electrostatic precipitation technology to eliminate surgical smoke and maintain a clear visual field during operations. The company distributes its products to hospitals across Europe, the Middle East, New Zealand, and Australia, leveraging its access to experienced surgeons and surgical trainers to identify challenges in surgical procedures and design effective solutions.

Carmat

Post in 2022
Carmat is a French medtech company that specializes in the development and manufacturing of bioprosthetic artificial hearts. Founded in 2008 and headquartered in Vélizy-Villacoublay, the company creates biocompatible, auto-regulated total artificial hearts designed to closely mimic the human heart's structure, including both right and left ventricles. These devices are intended for patients suffering from chronic terminal heart failure classified as class IV by the New York Heart Association, as well as those experiencing acute terminal heart failure due to massive myocardial infarction. Carmat aims to provide a reliable and innovative therapeutic solution for heart failure patients who are ineligible for transplants and have exhausted other treatment options. In addition to the artificial hearts, the company develops the necessary power supply systems and remote diagnostic systems for these devices.

Cailabs

Series C in 2022
CAILabs SAS is a French deep tech company headquartered in Rennes, specializing in the design, development, and production of photonic solutions aimed at optimizing light utilization in various applications. Established in 2013, CAILabs focuses on innovative optical components, particularly through its patented Multi-Plane Light Conversion (MPLC) technology. The company provides a range of products, including mode multiplexers, light converters, and laser beam shaping solutions tailored for the telecommunications and industrial laser sectors. Its offerings are designed to enhance the performance of fiber optic networks and laser material processing, addressing critical challenges such as atmospheric turbulence and the need for efficient signal multiplexing. CAILabs aims to leverage its expertise and technological innovations to create reliable and cost-effective solutions for clients in the photonics industry.

ONO

Series A in 2022
Creating transformative change in urban mobility, making our cities cleaner and more enjoyable. We first focus on urban logistics, moving goods around the city in ways that are sustainable, efficient and cost-effective. Our vehicle and its modular platform system, with easily swappable modular units, meets the needs of city logistics. From moving food to flowers to furniture, the possibilities are endless. ONO’s founders, pioneer in e-mobility solutions, Beres Seelbach, former head of design at Mercedes and Volkswagen, Murat Günak, and light electric vehicle expert and engineer, Philipp Kahle, sought to rethink and reshape modern urban transportation. They put together a forward-thinking group of designers, engineers and creative thinkers who shared their vision of transforming urban mobility. ONO is a Berlin-based e-mobility company introducing a whole new category of emissions-free vehicle: the Pedal Assisted Transporter (PAT), combining the flexibility of a bicycle with the capacity and durability of a van. We offer environmentally friendly urban logistics solutions designed and optimised for cities of today.

ROSI

Series A in 2022
ROSI is a company based in Grenoble, France, focused on developing innovative technologies for the recycling and revalorization of raw materials within the photovoltaic industry. The company specializes in recovering ultra-pure silicon and other metals that are typically lost during the manufacturing of photovoltaic cells and at the end of a solar panel's life cycle. By addressing industrial waste generated during the solar wafer slicing process and capturing silicon fine particles lost during PV-silicon production, ROSI enables its clients to produce photovoltaic modules in a more sustainable and cost-effective manner.

APIX Analytics

Venture Round in 2022
Founded in 2014, APIX Analytics specializes in developing miniaturized multigas analyzers systems. These systems integrate silicon-based analytical chains such as sampling, gas injection, and mixture separation to enhance specificity, detection, identification, and quantification of compounds.

Energy Dome

Venture Round in 2022
Energy Dome develops a low-cost, efficient system for long-duration electricity storage using liquid CO2. Its focus is on enabling dispatchable renewable energy production to facilitate the decarbonization of the energy industry and promote sustainability.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.